Design Therapeutics Reports Officer and Director Changes

TL;DR

Design Therapeutics is shuffling its execs and board members, effective Sept 9.

AI Summary

Design Therapeutics, Inc. filed an 8-K on September 10, 2025, reporting changes effective September 9, 2025. The filing indicates a departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with updates to compensatory arrangements for these officers.

Why It Matters

Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: medium — Changes in key leadership can introduce uncertainty regarding future strategy and performance.

Key Players & Entities

• Design Therapeutics, Inc. (company) — Registrant
• September 09, 2025 (date) — Effective date of reported changes
• September 10, 2025 (date) — Filing date of the 8-K

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share DSGN Nasdaq Glo
• $40,000 — receive an annual cash retainer of (a) $40,000 for service on the Board and (b) $12,00
• $12,000 — 40,000 for service on the Board and (b) $12,000 for service as chair of the Compensatio

Filing Documents

• dsgn-20250909.htm (8-K) — 44KB
• 0001807120-25-000004.txt ( ) — 154KB
• dsgn-20250909.xsd (EX-101.SCH) — 26KB
• dsgn-20250909_htm.xml (XML) — 5KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2025, Arsani William, M.D., tendered his resignation as a member of the board of directors (the "Board") of Design Therapeutics, Inc. (the "Company"), effective September 9, 2025 (the "Effective Date"), which was not the result of any disagreement with the Company on any matter related to its operations, policies or practices. On September 9, 2025, the Board appointed Justin Gover as a member of the Board as a Class III director, effective as of the Effective Date, with a term ending at the Company's 2027 annual meeting of stockholders. Mr. Gover was also appointed as chair of the Compensation Committee of the Board (the "Compensation Committee"). Pursuant to the Company's non-employee director compensation policy (the "Compensation Policy"), (i) Mr. Gover is entitled to receive an annual cash retainer of (a) $40,000 for service on the Board and (b) $12,000 for service as chair of the Compensation Committee, and (ii) Mr. Gover received (a) an initial option grant to purchase 30,000 shares of our common stock, which vests monthly over a three-year period, and (b) a prorated annual option grant to purchase 15,833 shares of our common stock, which vests monthly over a one-year period. The foregoing description of the Compensation Policy is qualified in its entirety by the full text of the Compensation Policy, a copy of which is filed as Exhibit 10.7 to the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the "SEC") on March 10, 2025. The Company and Mr. Gover have also entered into the Company's standard indemnification agreement for the Company's directors and officers, a copy of which is filed as Exhibit 10.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Design Therapeutics, Inc. Date: September 10, 2025 By: /s/ Pratik Shah, Ph.D. Pratik Shah, Ph.D. President, Chief Executive Officer and Chairperson

View Full Filing

View this 8-K filing on SEC EDGAR